Search results

Jump to: navigation, search

Page title matches

  • ...t cancer]].<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzumab--mechanism of action and use in clinical practice. | journal=N Engl J Med |
    707 B (88 words) - 16:35, 23 March 2010
  • 131 B (15 words) - 12:56, 5 February 2009
  • Auto-populated based on [[Special:WhatLinksHere/Trastuzumab]]. Needs checking by a human.
    457 B (58 words) - 02:04, 12 January 2010

Page text matches

  • ...t cancer]].<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzumab--mechanism of action and use in clinical practice. | journal=N Engl J Med |
    707 B (88 words) - 16:35, 23 March 2010
  • {{r|Trastuzumab}}
    640 B (83 words) - 23:38, 11 January 2010
  • ...t cancer]].<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzumab--mechanism of action and use in clinical practice. | journal=N Engl J Med |
    2 KB (308 words) - 11:03, 16 July 2010
  • ...that lengthens remission time in metastatic [[breast cancer]]."<ref>{{MeSH|Trastuzumab [Substance Name]}}</ref>
    10 KB (1,363 words) - 20:18, 1 July 2010
  • {{r|Trastuzumab}}"HER2 (Entrez protein) antibody that lengthens remission time in metastati
    4 KB (467 words) - 05:17, 6 February 2009
  • ...mab]] (Herceptin), a [[monoclonal antibody]] that targets this protein. [[Trastuzumab]] may be used both in the postsurgical setting (so-called "[[adjuvant]]" th ...eir growth.<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzumab--mechanism of action and use in clinical practice. | journal=N Engl J Med |
    101 KB (14,656 words) - 16:27, 18 August 2015
  • 13. Costantini, D, et. al. 111In-Labeled Trastuzumab (Herceptin) Modiļ¬ed with Nuclear Localization Sequences (NLS): An Auger E
    11 KB (1,563 words) - 08:38, 7 October 2013